Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?

Cancer Genetics and Cytogenetics

Volumn 194, Issue 1, 2009, Pages 12-22

  Gadji, Macoura ^a   Fortin, David ^a   Tsanaclis, Ana Maria ^b   Drouin, Régen ^a  

^a Faculty of Medicine and Health Sciences   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER CLASSIFICATION; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME ANALYSIS; CHROMOSOME ARM; CHROMOSOME DELETION; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENOME SIZE; GLIOSARCOMA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MICROSATELLITE MARKER; MOLECULAR GENETICS; MOLECULAR PROBE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 69549118409     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.05.004     Document Type: Article

References (50)

1. Reifenberger G., Kros J.M., Louis D.N., and Collins D.P. Oligodendrogliomas. In: Louis D.N., Ohgaki H., Wiestler O.D., and Cavenee W.K. (Eds). WHO classification of tumors of the central nervous system. 4th ed. World Health Organization Classification of Tumours (2007), WHO Press, Geneva 54-60
2. Berger M.S. Role of surgery in diagnosis and management. In: Apuzzo M.L.J. (Ed). American Association of neurological Surgeons (1995), Benign cerebral glioma, Park Ridge, IL 293-307
3. Behar T., McMorris F.A., Novotný E.A., Barker J.L., and Dubois-Dalcq M. Growth and differentiation properties of O-2A progenitors purified from rat cerebral hemispheres. J Neurosci Res 21 (1988) 168-180
4. Rorke L.B. Pathologic diagnosis as the gold standard. Cancer 79 (1997) 665-667
5. Burger P.C. What is an oligodendroglioma?. Brain Pathol 12 (2002) 257-259
6. Bigner S.H., Rasheed B.K., Wiltshire R., and McLendon R.E. Morphologic and molecular genetic aspects of oligodendroglial neoplasms. Neuro Oncol 1 (1999) 52-60
7. Hatanpaa K.J., Burger P.C., Eshleman J.R., Murphy K.M., and Berg K.D. Molecular diagnosis of oligodendroglioma in paraffin sections. Lab Invest 83 (2003) 419-428
8. Van den Bent M.J., Reni M., Gatta G., and Vecht C. Oligodendroglioma. Crit Rev Oncol Hematol 66 (2008) 262-272
9. Giannini C., Burger P.C., Berkey B.A., Cairncross J.G., Jenkins R.B., Mehta M., Curran W.J., and Aldape K. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 18 (2008) 360-369
10. Cairncross J.G., Ueki K., Zlatescu M.C., Lisle D.K., Finkelstein D.M., Hammond R.R., Silver J.S., Stark P.C., Macdonald D.R., Ino Y., Ramsay D.A., and Louis D.N. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90 (1998) 1473-1479
11. Burger P.C., Minn A.Y., Smith J.S., Borell T.J., Jedlicka A.E., Huntley B.K., Goldthwaite P.T., Jenkins R.B., and Feuerstein B.G. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma: a study of paraffin-embedded sections. Mod Pathol 14 (2001) 842-853
12. Sasaki H., Zlatescu M.C., Betensky R.A., Johnk L.B., Cutone A.N., Cairncross J.G., and Louis D.N. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade oligodendroglioma. J Neuropathol Exp Neurol 61 (2002) 58-63
13. Ueki K., Nishikawa R., Nakazato Y., Hirose T., Hirato J., Funada N., Fujimaki T., Hojo S., Kubo O., Ide T., Usui M., Ochiai C., Ito S., Takahashi H., Mukasa A., Asai A., and Kirino T. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 8 (2002) 196-201
14. Jeuken J.W., von Deimling A., and Wesseling P. Molecular pathogenesis of oligodendroglial tumors. J Neurooncol 70 (2004) 161-181
15. Okamoto Y., Di Patre P.L., Burkhard C., Horstmann S., Jourde B., Fahey M., Schuler D., Probst-Hensch N.M., Yasargil M.G., Yonekawa Y., Lutolf U.M., Kleihues P., and Ohgaki H. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108 (2004) 49-56
16. Reifenberger G., and Louis D.N. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62 (2003) 111-126
17. Smith J.S., Perry A., Borell T.J., Lee H.K., O'Fallon J., Hosek S.M., Kimmel D., Yates A., Burger P.C., Scheithauer B.W., and Jenkins R.B. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18 (2000) 636-645
18. Godfraind C., Rousseau E., Ruchoux M.M., Scaravilli F., and Vikkula M. Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. Neuropathol Appl Neurobiol 29 (2003) 462-471
19. Iwamoto F.M., Nicolardi L., Demopoulos A., Barbashina V., Salazar P., Rosenblum M., and Hormigo A. Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J Neurooncol 88 (2008) 293-298
20. Bouvier C., Roll P., Quilichini B., Metellus P., Calisti A., Gilles S., Chinot O., Fina F., Martin P.M., and Figarella-Branger D. Deletions of chromosomes 1p and 19q are detectable on frozen smears of gliomas by FISH: usefulness for stereotactic biopsies. J Neurooncol 68 (2004) 141-149
21. Perry A., Fuller C.E., Banerjee R., Brat D.J., and Scheithauer B.W. Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Biosci 8 (2003) a1-a9
22. Fuller C.E., Schmidt R.E., Roth K.A., Burger P.C., Scheithauer B.W., Banerjee R., Trinkaus K., Lytle R., and Perry A. Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features. J Neuropathol Exp Neurol 62 (2003) 1118-1128
23. Jeon Y.K., Park K., Park C.K., Paek S.H., Jung H.W., and Park S.H. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization. Neuropathology 27 (2007) 10-20
24. Hamlat A., Saikali S., Chaperon J., Le Calve M., Gedouin D., Ben-Hassel M., and Guegan Y. Oligodendroglioma: clinical study and survival analysis correlated with chromosomal anomalies. Neurosurg Focus 19 5 (2005) E15
25. Reddy K.S. Assessment of 1p/19q deletions by fluorescence in situ hybridization in gliomas. Cancer Genet Cytogenet 184 (2008) 77-86
26. Cairncross J.G., and Macdonald D.R. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23 (1988) 360-364
27. Kumar-Sinha C., Tomlins S.A., and Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8 (2008) 497-511
28. Drouin R., Therrien J.P., Angers M., and Ouellet S. In vivo DNA analysis. Methods Mol Biol 148 (2001) 175-219
29. In: Louis D.N., Ohgak H., Wiestler O.D., and Cavenee W.K. (Eds). WHO classification of tumours of the central nervous system. 9th ed. World Health Organization Classification of Tumours. Geneva: (2007), WHO Press
30. Coons S.W., Johnson P.C., Scheithauer B.W., Yates A.J., and Pearl D.K. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79 (1997) 1381-1393
31. Giannini C., Scheithauer B.W., Weaver A.L., Burger P.C., Kros J.M., Mork S., Graeber M.B., Bauserman S., Buckner J.C., Burton J., Riepe R., Tazelaar H.D., Nascimento A.G., Crotty T., Keeney G.L., Pernicone P., and Altermatt H. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 60 (2001) 248-262
32. Kros J.M., Gorlia T., Kouwenhoven M.C., Zheng P.P., Collins V.P., Figarella-Branger D., Giangaspero F., Giannini C., Mokhtari K., Mork S.J., Paetau A., Reifenberger G., and van den Bent M.J. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 66 (2007) 545-551
33. Megyesi J.F., Kachur E., Lee D.H., Zlatescu M.C., Betensky R.A., Forsyth P.A., Okada Y., Sasaki H., Mizoguchi M., Louis D.N., and Cairncross J.G. Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 10 (2004) 4303-4306
34. Dehais C., Laigle-Donadey F., Marie Y., Kujas M., Lejeune J., Benouaich-Amiel A., Pedretti M., Polivka M., Xuan K.H., Thillet J., Delattre J.Y., and Sanson M. Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer 107 (2006) 1891-1897
35. Nagasaka T., Gunji M., Hosokai N., Hayashi K., Ikeda H., Ito M., and Inao S. FISH 1p/19q deletion/imbalance for molecular subclassification of glioblastoma. Brain Tumor Pathol 24 (2007) 1-5
36. Kanner A.A., Staugaitis S.M., Castilla E.A., Chernova O., Prayson R.A., Vogelbaum M.A., Stevens G., Peereboom D., Suh J., Lee S.Y., Tubbs R.R., and Barnett G.H. The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. J Neurosurg 104 (2006) 542-550
37. Nutt C.L. Molecular genetics of oligodendrogliomas: a model for improved clinical management in the field of neurooncology. Neurosurg Focus 19 5 (2005) E2
38. Bigner S.H., Matthews M.R., Rasheed B.K., Wiltshire R.N., Friedman H.S., Friedman A.H., Stenzel T.T., Dawes D.M., McLendon R.E., and Bigner D.D. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 155 (1999) 375-386
39. Koschny R., Koschny T., Froster U.G., Krupp W., and Zuber M.A. Comparative genomic hybridization in glioma: a meta-analysis of 509 cases. Cancer Genet Cytogenet 135 (2002) 147-159
40. Bourdon V., Plessis G., Chapon F., Guarnieri J., Derlon J.M., and Jonveaux P. Chromosome imbalances in oligodendroglial tumors detected by comparative genomic hybridization. Ann Genet 47 (2004) 105-111
41. Jeuken J.W., Sprenger S.H., Boerman R.H., von Deimling A., Teepen H.L., van Overbeeke J.J., and Wesseling P. Subtyping of oligo-astrocytic tumours by comparative genomic hybridization. J Pathol 194 (2001) 81-87
42. Cowell J.K., Barnett G.H., and Nowak N.J. Characterization of the 1p/19q chromosomal loss in oligodendrogliomas using comparative genomic hybridization arrays (CGHa). J Neuropathol Exp Neurol 63 (2004) 151-158
43. Kitange G., Misra A., Law M., Passe S., Kollmeyer T.M., Maurer M., Ballman K., Feuerstein B.G., and Jenkins R.B. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. Genes Chromosomes Cancer 42 (2005) 68-77
44. Scheie D., Andresen P.A., Cvancarova M., Bo A.S., Helseth E., Skullerud K., and Beiske K. Fluorescence in situ hybridization (FISH) on touch preparations: a reliable method for detecting loss of heterozygosity at 1p and 19q in oligodendroglial tumors. Am J Surg Pathol 30 (2006) 828-837
45. Fallon K.B., Palmer C.A., Roth K.A., Nabors L.B., Wang W., Carpenter M., Banerjee R., Forsyth P., Rich K., and Perry A. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 63 (2004) 314-322
46. Ino Y., Betensky R.A., Zlatescu M.C., Sasaki H., Macdonald D.R., Stemmer-Rachamimov A.O., Ramsay D.A., Cairncross J.G., and Louis D.N. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7 (2001) 839-845
47. Hashimoto N., Murakami M., Takahashi Y., Fujimoto M., Inazawa J., and Mineura K. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p. Cancer 97 (2003) 2254-2261
48. Hartmann C., Mueller W., and von Deimling A. Pathology and molecular genetics of oligodendroglial tumors. J Mol Med 82 (2004) 638-655
49. Jenkins R.B., Blair H., Ballman K.V., Giannini C., Arusell R.M., Law M., Flynn H., Passe S., Felten S., Brown P.D., Shaw E.G., and Buckner J.C. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66 (2006) 9852-9861
50. Griffin C.A., Burger P., Morsberger L., Yonescu R., Swierczynski S., Weingart J.D., and Murphy K.M. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 65 (2006) 988-994